Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease
Part of paid clinical trials in Ann Arbor, Michigan.
- Sponsor
- University of Michigan
- Study ID
- NCT07556718
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Quiescent Crohn's Disease (CD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Amitriptyline — DRUGAmitriptyline will be administered orally once daily. It will be dispensed in capsules or tablets that are visually identical to placebo. Self-titration schedule beginning at 10 mg and increasing to a maximum of 50 mg over the first six weeks, as tolerated. Participants will continue their maximum tolerated dose through Week 24.
- Placebo — DRUGPlacebo capsules or tablets will be visually indistinguishable from amitriptyline to maintain participant and investigator blinding. Self-titration schedule beginning at 10 mg and increasing to a maximum of 50 mg over the first six weeks, as tolerated. Participants will continue their maximum tolerated placebo dose through Week 24.
Study Details
Many individuals with Crohn's disease continue to experience abdominal pain, bloating, or bowel habit changes even when their inflammation is controlled. Amitriptyline is a medication commonly used at low doses to treat irritable bowel syndrome (IBS) and abdominal pain. This study will assess whether amitriptyline is safe and reduces those ongoing GI symptoms in adults with Crohn's disease in remission.
Key Dates
- Start date
- Jun 3, 2026
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: AmitriptylineRoughly 50 participants
- Placebo Comparator: PlaceboRoughly 50 participants
Primary Outcome Measure
Safety reported as the proportion of participants experiencing a serious adverse event (SAE), [ Time Frame: Week 24 ]
Central Contacts
- Charlie Bourque Jr.(734) 615-3911
- Allen A. Lee, MD, MS(734) 936-9454
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Michigan | Ann Arbor | Michigan | 48109 |
Find similar trials in Ann Arbor, MI
By research site